Aurinia Pharmaceuticals (AUPH) Assets Average (2017 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Assets Average came in at $737.8 million in Q1 2026, up 39.8% YoY from $527.7 million in Q1 2025, and up 15.36% on a QoQ basis from $639.6 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Assets Average (2017 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 9 years of Assets Average data on file, last reported at $737.8 million in Q1 2026.
- Quarterly Assets Average rose 39.8% year-over-year to $737.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $737.8 million (up 39.8% YoY) and the FY2025 annual result came in at $651.1 million, up 18.52% from the prior year.
- Assets Average climbed to $737.8 million in Q1 2026, from $639.6 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $737.8 million in Q1 2026 to a low of $461.3 million in Q1 2023.
- A 5-year average of $536.0 million and a median of $525.1 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average dropped 12.15% — and 2026, when it surged 39.8%.
- Tracing AUPH's Assets Average over 5 years: stood at $479.6 million in 2022, then grew by 15.01% to $551.5 million in 2023, then slipped by 0.28% to $550.0 million in 2024, then increased by 16.28% to $639.6 million in 2025, then gained by 15.36% to $737.8 million in 2026.
- The last three Assets Average figures came in at $737.8 million (Q1 2026), $639.6 million (Q4 2025), and $515.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 758.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 758.13 Mn |
| Mar 31, 2026 | 737.79 Mn |
| Dec 31, 2025 | 639.56 Mn |
| Sep 30, 2025 | 515.05 Mn |
| Jun 30, 2025 | 503.71 Mn |
| Mar 31, 2025 | 527.75 Mn |
| Dec 31, 2024 | 550.00 Mn |
| Sep 30, 2024 | 536.45 Mn |
| Jun 30, 2024 | 520.08 Mn |
| Mar 31, 2024 | 532.35 Mn |
| Dec 31, 2023 | 551.54 Mn |
| Sep 30, 2023 | 551.96 Mn |
| Jun 30, 2023 | 500.33 Mn |
| Mar 31, 2023 | 461.31 Mn |
| Dec 31, 2022 | 479.58 Mn |
| Sep 30, 2022 | 485.22 Mn |
| Jun 30, 2022 | 494.53 Mn |
| Mar 31, 2022 | 525.13 Mn |
| Dec 31, 2021 | 451.72 Mn |
| Sep 30, 2021 | 373.17 Mn |